Mediation of inflammation by cyclooxygenase-2 - PubMed (original) (raw)
Review
Mediation of inflammation by cyclooxygenase-2
K Seibert et al. Agents Actions Suppl. 1995.
Abstract
Non-steroidal antiinflammatory drugs (NSAIDs) are commonly used for the treatment of inflammation, pain, and fever. Mechanistically, these compounds are believed to act via inhibition of the enzyme cyclooxygenase (COX), which catalyzes the conversion of arachidonic acid to the prostaglandins (PGs). Although commercially available NSAIDS are efficacious antiinflammatory agents, significant side effects limit their use. Recently two forms of COX were identified- a constitutively expressed COX-1 and a cytokine-inducible COX-2. Commercially available NSAIDs like indomethacin inhibit both COX-1 and COX-2 suggesting the hypothesis that toxicities associated with NSAID therapy are due to inhibition of the non-regulated or constitutive form of COX (COX-1) in normal tissues, whereas therapeutic benefit derives from inhibition of the inducible enzyme, COX-2, at the site of inflammation. Therefore, a selective inhibitor of COX-2 may be anti-inflammatory without GI toxicity-providing a significant improvement over currently available NSAIDs.
Similar articles
- Distribution of COX-1 and COX-2 in normal and inflamed tissues.
Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Seibert K, et al. Adv Exp Med Biol. 1997;400A:167-70. doi: 10.1007/978-1-4615-5325-0_24. Adv Exp Med Biol. 1997. PMID: 9547553 - Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A, Ottani A, Sandrini M. Bertolini A, et al. Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872. Pharmacol Res. 2001. PMID: 11735348 Review. - New NSAIDs and gastroduodenal damage.
Folco GC. Folco GC. Ital J Gastroenterol. 1996 Dec;28 Suppl 4:28-9. Ital J Gastroenterol. 1996. PMID: 9032579 Review. - Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks.
Bertolini A, Ottani A, Sandrini M. Bertolini A, et al. Curr Med Chem. 2002 May;9(10):1033-43. doi: 10.2174/0929867024606650. Curr Med Chem. 2002. PMID: 12733982 Review.
Cited by
- Renal and testicular up-regulation of pro-inflammatory chemokines (RANTES and CCL2) and cytokines (TNF-α, IL-1β, IL-6) following acute edible camphor administration is through activation of NF-kB in rats.
Somade OT, Ajayi BO, Safiriyu OA, Oyabunmi OS, Akamo AJ. Somade OT, et al. Toxicol Rep. 2019 Jul 31;6:759-767. doi: 10.1016/j.toxrep.2019.07.010. eCollection 2019. Toxicol Rep. 2019. PMID: 31413946 Free PMC article. - Prim-O-glucosylcimifugin Attenuates Lipopolysaccharideinduced Inflammatory Response in RAW 264.7 Macrophages.
Zhou J, Sun YY, Sun MY, Mao WA, Wang L, Zhang J, Zhang H. Zhou J, et al. Pharmacogn Mag. 2017 Jul-Sep;13(51):378-384. doi: 10.4103/pm.pm_323_16. Epub 2017 Jul 19. Pharmacogn Mag. 2017. PMID: 28839360 Free PMC article. - COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis.
Muthian G, Raikwar HP, Johnson C, Rajasingh J, Kalgutkar A, Marnett LJ, Bright JJ. Muthian G, et al. J Clin Immunol. 2006 Jan;26(1):73-85. doi: 10.1007/s10875-006-8787-y. J Clin Immunol. 2006. PMID: 16418805 - Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.
El-Malah AA, Gineinah MM, Deb PK, Khayyat AN, Bansal M, Venugopala KN, Aljahdali AS. El-Malah AA, et al. Pharmaceuticals (Basel). 2022 Jul 3;15(7):827. doi: 10.3390/ph15070827. Pharmaceuticals (Basel). 2022. PMID: 35890126 Free PMC article. Review. - Safety and effectiveness of 4-week therapy with aceclofenac controlled release once a day.
Jeong JC, Chung YH, Park T, Park SY, Jung TW, Abd El-Aty AM, Bang JS, Jeong JH. Jeong JC, et al. Sci Rep. 2022 Oct 3;12(1):16519. doi: 10.1038/s41598-022-20633-6. Sci Rep. 2022. PMID: 36192565 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials